Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis

Journal of Rheumatology

Volumn 34, Issue 10, 2007, Pages 2063-2069

  Giusti, Laura ^a   Bazzichi, Laura ^a   Baldini, Chiara ^a   Ciregia, Federica ^a   Mascia, Giovanni ^a   Giannaccini, Gino ^a   Del Rosso, Mario ^b   Bombardieri, Stefano ^a   Lucacchini, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Proteomics; Saliva; Systemic sclerosis

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; BETA 2 MICROGLOBULIN; CALGRANULIN; CYCLOPHILIN A; CYSTATIN B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; KERATIN; PSORIASIN; SALIVA PROTEIN; TRIOSEPHOSPHATE ISOMERASE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SALIVA ANALYSIS; SYSTEMIC SCLEROSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; CROSS-SECTIONAL STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MIDDLE AGED; PEPTIDE MAPPING; PEPTIDES; SALIVA; SALIVARY PROTEINS; SCLERODERMA, SYSTEMIC;

EID: 35148856817     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Atzeni F, Bardoni A, Cutolo M, et al. Localized and systemic forms of scleroderma in adults and children. Clin Exp Rheumatol 2006;24:S36-45.
2. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002;4:99-107.
3. Medsger TA Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000;12:545-8.
4. Mason GI, Hamburger J, Matthews JB. Mast cells, extracellular matrix components, TGFβ isoforms and TGFβ receptor expression in labial salivary glands in systemic sclerosis. Ann Rheum Dis 2000;59:183-9.
5. Jun JB, Kuechle M, Harlan JM, Elkon KB. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 2003;15:756-60.
6. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
7. Worda M, Sgonc R, Dietrich H, et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorioallantoic membrane assay. Arthritis Rheum 2003;48:2605-14.
8. Ihn H, Sato S, Fujimoto M, et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000;119:203-9.
9. Kissin E, Korn JH. Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis. Curr Rheumatol Rep 2002;4:129-35.
10. Fujii H, Hasegawa M, Takehara K, Mukaida N, Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 2002;130:546-56.
11. Widom RL. Regulation of matrix biosynthesis and degradation in systemic sclerosis. Curr Opin Rheumatol 2000;12:534-9.
12. Sakkas LI, Xu B, Arlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649-59.
13. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
14. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
15. Giusti L, Baldini C, Bazzichi L, et al. Proteome analysis of whole saliva: a new tool for rheumatic diseases - the example of Sjögren's syndrome. Proteomics 2007;7:1634-43.
16. Ryu OH, Atkinson JC, Hoehn GT, Illei GG, Hart TC. Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology Oxford 2006;45:1077-86.
17. Ruiz-Romero C, Lopez-Armada MJ, Blanco FJ. Proteomic characterization of human normal articular chondrocytes: a novel tool for the study of osteoarthritis and other rheumatic diseases. Proteomics 2005;5:3048-59.
18. Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5:1423-30.
19. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
20. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
21. Hochstrasser DF, Patchornik A, Merril CR. Development of polyacrylamide gels that improve the separation of proteins and their detection by silver staining. Anal Biochem 1988;173:412-23.
22. Candiano G, Bruschi M, Musante L, et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004;25:1327-33.
23. Heizmann CW, Schafer BW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996;21:134-40.
24. Fagerhol MK, Munthe E, Berntzen HB, Olmez U. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991;20:74-82.
25. Aadland E, Schjønsby H, Røseth AG, Fagerhol MK. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
26. Stulik J, Osterreicher J, Koupilova K, et al. The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis 1999;20:1047-54.
27. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113-23.
28. Los M, Hashemi M, Sorg C, Karami-Tehrani F, Ghavami S, Kerkhoff C. Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J Leukoc Biol 2004;76:169-75.
29. Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. J Clin Pathol: Mol Pathol 2001;54:289-92.
30. Sakkas LI. New developments in the pathogenesis of systemic sclerosis. Autoimmunity 2005;38:113-6.
31. Watson PH, Leygue ER, Murphy LC. Psoriasin (S100A7). Int J Biochem Cell Biol 1998;30:567-71.
32. Ostergaard M, Wolf H, Orntoft TF, Celis JE. Psoriasin (S100A7): A putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 1999;20:349-54.
33. Guo T, Rudnick PA, Wang W, Lee CS, DeVoe DL, Balgley BM. Characterization of the human salivary proteome by capillary isoelectric focusing/nanoreversed- phase liquid chromatography coupled with ESI-tandem MS. J Proteome Res 2006;5:1469-78.
34. Weiner OD, Servant G, Welch MD, Mitchison TJ, Sedat JW, Bourne HR. Spatial control of actin polymerization during neutrophil Chemotaxis. Nat Cell Biol 1999;1:75-81.
35. Matsumoto I, Maccioni M, Lee DM, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nature Immunol 2002;3:360-5.
36. Watanabe H, Seino T, Sato Y. Antibodies to triosephosphate isomerase in patients with neuropsychiatric lupus. Biochem Biophys Res Comm 2004;321:949-53.
37. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002;295:1852-8.
38. Kim SH, Lessner SM, Sakurai Y, Galis ZS. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol 2004;164:1567-74.